Security Snapshot

Arcus Biosciences, Inc. - Common Stock (RCUS) Institutional Ownership

CUSIP: 03969F109

13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

206

Shares (Excl. Options)

121,424,270

Price

$23.83

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
RCUS on NYSE
Shares outstanding
122,470,452
Price per share
$21.60
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
121,424,270
Total reported value
$2,893,303,857
% of total 13F portfolios
0%
Share change
+19,415,272
Value change
+$498,497,157
Number of holders
206
Price from insider filings
$21.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • RCUS - Arcus Biosciences, Inc. - Common Stock is tracked under CUSIP 03969F109.
  • 206 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 206 to 18 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,893,303,857 to $5,162,999.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 206 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 03969F109?
CUSIP 03969F109 identifies RCUS - Arcus Biosciences, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Arcus Biosciences, Inc. - Common Stock (RCUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 26% -14% $427,376,736 31,424,760 0% GILEAD SCIENCES, INC. 03 Nov 2025
BlackRock, Inc. 10% +11% $303,514,602 +$65,766,227 12,736,927 +28% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.1% -28% $58,921,714 -$20,381,232 4,332,479 -26% Point72 Asset Management, L.P. 30 Sep 2025

As of 31 Dec 2025, 206 institutional investors reported holding 121,424,270 shares of Arcus Biosciences, Inc. - Common Stock (RCUS). This represents 99% of the company’s total 122,470,452 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arcus Biosciences, Inc. - Common Stock (RCUS) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 26% 31,424,760 0% 39% $748,852,031
BlackRock, Inc. 12% 14,997,891 +27% 0.01% $357,399,743
VANGUARD GROUP INC 6.5% 7,962,874 +20% 0% $189,755,288
SUVRETTA CAPITAL MANAGEMENT, LLC 4.2% 5,188,858 +41% 3.1% $123,650,486
WELLINGTON MANAGEMENT GROUP LLP 4.2% 5,184,509 +309% 0.02% $123,546,849
STATE STREET CORP 3.7% 4,576,969 +35% 0% $109,069,171
Woodline Partners LP 3.1% 3,769,788 +0% 0.35% $89,834,048
MARSHALL WACE, LLP 2.8% 3,387,794 0.08% $80,731,131
Point72 Asset Management, L.P. 2.7% 3,280,000 -24% 0.12% $78,162,400
Siren, L.L.C. 2.5% 3,007,077 +3.3% 2.1% $71,658,645
Fisher Asset Management, LLC 1.6% 1,949,788 +167% 0.02% $46,463,447
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,907,345 +19% 0% $45,459,101
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,687,374 +19% 0.05% $40,210,000
SAMLYN CAPITAL, LLC 1.3% 1,604,270 0.61% $38,229,753
DIMENSIONAL FUND ADVISORS LP 1.2% 1,524,157 +1.4% 0.01% $36,316,719
TORONTO DOMINION BANK 1.2% 1,484,699 0.06% $35,380,377
MORGAN STANLEY 0.99% 1,210,754 -21% 0% $28,852,291
GOLDMAN SACHS GROUP INC 0.95% 1,168,437 +23% 0% $27,843,854
FMR LLC 0.93% 1,135,178 -51% 0% $27,051,284
BARCLAYS PLC 0.91% 1,112,258 +528% 0.01% $26,505,110
Sofinnova Investments, Inc. 0.9% 1,096,705 -10% 1.1% $26,134,480
BANK OF AMERICA CORP /DE/ 0.82% 1,000,818 -26% 0% $23,849,494
Parkman Healthcare Partners LLC 0.79% 968,602 +48% 2.2% $23,081,786
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.79% 968,241 +11% 0% $23,073,183
JACOBS LEVY EQUITY MANAGEMENT, INC 0.76% 929,981 -17% 0.09% $22,161,447

Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 239,057 $5,162,999 +$720,312 $21.60 18
2025 Q4 121,424,270 $2,893,303,857 +$498,497,157 $23.83 206
2025 Q3 100,610,243 $1,368,169,306 +$17,470,409 $13.60 186
2025 Q2 99,735,332 $811,386,525 +$23,005,595 $8.14 181
2025 Q1 97,195,653 $762,981,433 +$76,941,552 $7.85 183
2024 Q4 83,908,968 $1,249,338,646 -$21,214,675 $14.89 185
2024 Q3 53,324,923 $815,463,718 +$21,618,657 $15.29 184
2024 Q2 51,955,193 $791,285,512 -$15,709,425 $15.23 191
2024 Q1 52,828,671 $997,275,069 +$741,376 $18.88 169
2023 Q4 52,818,611 $1,008,878,346 -$1,266,933 $19.10 181
2023 Q3 52,811,112 $947,947,087 -$30,726,648 $17.95 184
2023 Q2 54,702,646 $1,110,123,478 -$11,409,103 $20.31 177
2023 Q1 55,490,875 $1,012,137,432 +$17,396,401 $18.24 177
2022 Q4 53,808,832 $1,112,728,096 +$17,661,819 $20.68 199
2022 Q3 52,505,739 $1,373,608,654 -$54,087 $26.16 171
2022 Q2 52,444,913 $1,329,092,467 -$15,970,235 $25.34 162
2022 Q1 50,609,470 $1,598,261,880 -$43,817,366 $31.56 146
2021 Q4 50,826,972 $2,056,609,533 +$107,109,155 $40.47 136
2021 Q3 48,251,727 $1,682,950,642 +$59,932,851 $34.87 127
2021 Q2 45,147,112 $1,239,729,813 +$11,589,356 $27.46 125
2021 Q1 44,736,322 $1,254,917,338 +$7,899,154 $28.08 143
2020 Q4 44,575,673 $1,157,187,273 +$10,417,742 $25.96 143
2020 Q3 44,391,126 $760,991,949 +$17,571,170 $17.14 127
2020 Q2 41,840,912 $1,034,233,021 +$380,488,277 $24.74 138
2020 Q1 26,992,583 $374,653,368 -$448,171 $13.88 92
2019 Q4 23,560,774 $237,962,351 -$3,030,738 $10.10 74
2019 Q3 25,809,690 $234,896,496 -$672,043 $9.10 73
2019 Q2 26,440,928 $210,047,107 +$6,023,856 $7.95 76
2019 Q1 25,799,127 $322,227,437 -$12,715,178 $12.49 63
2018 Q4 26,918,679 $289,911,060 -$4,742,182 $10.77 66
2018 Q3 22,437,315 $312,774,356 +$950,561 $13.94 56
2018 Q2 22,392,855 $274,091,081 +$31,576,470 $12.24 61
2018 Q1 16,255,471 $250,516,107 +$250,516,106 $15.44 55